Last reviewed · How we verify
AG-221
At a glance
| Generic name | AG-221 |
|---|---|
| Also known as | CC-90007; Enasidenib; Idhifa, Enasidenib |
| Sponsor | Celgene |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- NAUSEA
- DIARRHOEA
- HYPOKALAEMIA
- DECREASED APPETITE
- THROMBOCYTOPENIA
- ANAEMIA
- FATIGUE
- VOMITING
- BLOOD BILIRUBIN INCREASED
- PYREXIA
- DYSPNOEA
- OEDEMA PERIPHERAL
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) (PHASE2)
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) (PHASE2)
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) (PHASE1)
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation (PHASE2)
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation (PHASE2)
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy (PHASE1, PHASE2)
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG-221 CI brief — competitive landscape report
- AG-221 updates RSS · CI watch RSS
- Celgene portfolio CI